Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma
Public ClinicalTrials.gov record NCT00030589. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Muliticenter, Dose-Reandomized Evaluation Of Targretin Capsules Plus PUVA In Patients With Stage IB - IIA Cutaneous T-Cell Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill cancer cells. Photosensitizing drugs, such as methoxsalen, are absorbed by cancer cells and, when exposed to light, become active and kill the cancer cells. Combining chemotherapy with photodynamic therapy may be an effective treatment for cutaneous T-cell lymphoma. PURPOSE: Randomized phase II trial to study the effectiveness of combining different doses of bexarotene with photodynamic therapy in treating patients who have stage IB or stage IIA cutaneous T-cell lymphoma.
Study identification
- NCT ID
- NCT00030589
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2001 (Type not available)
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Dec 18, 2013
Started 2001
United States locations
- U.S. sites
- 19
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham Comprehensive Cancer Center | Birmingham | Alabama | 35294-3300 | — |
| University of Arkansas for Medical Sciences | Little Rock | Arkansas | 72205 | — |
| Stanford University Medical Center | Stanford | California | 94305 | — |
| University of Colorado Health Science Center | Aurora | Colorado | 80010-0510 | — |
| H. Lee Moffitt Cancer Center and Research Institute | Tampa | Florida | 33612-9497 | — |
| Northwestern University Medical Center | Chicago | Illinois | 60611 | — |
| Rush-Presbyterian-St. Luke's Medical Center | Chicago | Illinois | 60612 | — |
| Tulane University School of Medicine | New Orleans | Louisiana | 70112 | — |
| Not listed | Slidell | Louisiana | 70459-0059 | — |
| Boston Medical Center | Boston | Massachusetts | 02118-2393 | — |
| Barbara Ann Karmanos Cancer Institute | Detroit | Michigan | 48201-1379 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| StonyBrook Dermatology Associates, P.C. | East Setauket | New York | 11733 | — |
| St. Luke's-Roosevelt Hospital Center - Roosevelt Division | New York | New York | 10019 | — |
| Ireland Cancer Center | Cleveland | Ohio | 44106-5065 | — |
| Knoxville Dermatology Group, P.C. | Knoxville | Tennessee | 37920 | — |
| Simmons Cancer Center - Dallas | Dallas | Texas | 75235-9154 | — |
| University of Texas - MD Anderson Cancer Center | Houston | Texas | 77030-4009 | — |
| Not listed | Tyler | Texas | 75703 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00030589, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 18, 2013 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00030589 live on ClinicalTrials.gov.